Nirsevimab

Chemical data

Drug data · ChEMBL

Max clinical phase

Approved

Molecule type

Antibody

First approval

2022

Admin. routes

parenteral

Indications

Respiratory Syncytial Virus Infection, infection

via ChEMBL · EBI

💊Medication

Generic name

Nirsevimab

Brand names

Beyfortus

Drug class

Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody, Fusion Protein Inhibitors

Route

Intramuscular

Type

Human Prescription Drug

Manufacturer

Sanofi Vaccines US Inc.

Indications: 1 INDICATIONS AND USAGE BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season. Children up to 24 months of age who remain vulnerable to severe RSV disease through their… (per FDA label)

• PHASE3COMPLETED
  Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of LifeSanofi Pasteur, a Sanofi Company · NCT05437510
• RECRUITING
  Prevention Strategy for Respiratory Syncytial Virus (RSV) Infections in Infants in FranceAssistance Publique - Hôpitaux de Paris · NCT06881953
• COMPLETED
  Effectiveness of Nirsevimab in Children Hospitalised With RSV BronchiolitisCentre Hospitalier Intercommunal Creteil · NCT06030505
• RECRUITING
  Evaluation of the Effect of Nirsevimab on Hospitalizations Due to RSV Infection in Infants Under One Year of Age.Meyer Children's Hospital IRCCS · NCT06856967
• NOT_YET_RECRUITING
  The Effectiveness of Early Immunisation With Nirsevimab on Preschool Wheezing in France, Based on an Analysis of Data From the French Health System Database.Hospices Civils de Lyon · NCT07317141
• COMPLETED
  Real-World Effectiveness of Nirsevimab Against RSV-Related and All-Cause Respiratory Tract Infections in Chinese InfantsHan Tongyan · NCT07382219

via ClinicalTrials.gov

Wikidata facts

Instance of

monoclonal antibody

via Wikidata · CC0